Drug Trial Radar · NCT07105488
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
225
Planned (sponsor's estimate)
Start
Jul 15, 2025
Primary completion
Feb 28, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Bluefin Biomedicine, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Conditions
- Atopic Dermatitis (AD)
Interventions
BFB759Biological
BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including atopic dermatitis
PlaceboDrug
Placebo for BFB759
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of BFB759 in ADTime frame: week 16 and week 32
Locations
88 sites in 7 countries. Site status is shown where the registry gives one.
Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute
Phoenix, Arizona
Skin Cancer and Dermatology Institute
Phoenix, Arizona
T. Joseph Raoof Md, Inc
Encino, California
Marvel Clinical Research
Huntington Beach, California
Antelope Valley Clinical Trials
Lancaster, California
Probity Medical Research
Los Angeles, California
NorCal Clinical Research
Rocklin, California
Focus Clinical Research, LLC -S
West Hills, California
Skin Care Research
Boca Raton, Florida
Florida Academic Dermatology Center Res and Edu, LLC
Coral Gables, Florida
Center for Skin Science and Innovation
Fort Lauderdale, Florida
Gsi Clinical Research
Margate, Florida
Ziaderm Research LLC
North Miami Beach, Florida
Lenus Research & Medical Group, LLC
Sweetwater, Florida
Clinical Trials Management - S
Tampa, Florida
Conquest Research LLC
Winter Park, Florida
Skin Cancer and Dermatology Institute
Douglasville, Georgia
Southeast Research Specialists, LLC
Douglasville, Georgia
The Indiana Clinical Trials Center
Plainfield, Indiana
Clinical Trials Management - S
Covington, Louisiana
Clinical Trials Management, LLC
Metairie, Louisiana
MetroBoston Clinical Partners
Brighton, Massachusetts
Oakland Hills Dermatology
Auburn Hills, Michigan
MI Skin Innovations
Northville, Michigan
Medisearch, LLC
Saint Joseph, Missouri
Elias Research Associates
Missoula, Montana
JDR Dermatology Research
Las Vegas, Nevada
Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute
Reno, Nevada
Skin Cancer and Dermatology Institute
Reno, Nevada
Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute
Sparks, Nevada
Skin Cancer and Dermatology Institute
Sparks, Nevada
Schweiger Dermatology, PC R.D.
Hackensack, New Jersey
Bobby Buka, MD (The Dermatology Specialist)
New York, New York
Bobby Buka, MD
New York, New York
Equity Medical, LLC
The Bronx, New York
Vitality Clinical Trials LLC
Woodbury, New York
DJL Clinical Research
Charlotte, North Carolina
Optima Research-Boardman
Boardman, Ohio
Apex Clinical Research Center, LLC
Canton, Ohio
Apex Clinical Research Center, LLC
Mayfield Heights, Ohio
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.